Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 6 points (0.0%) at 17,798 as of Tuesday, Nov. 24, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,309 issues advancing vs. 1,608 declining with 176 unchanged.

The Drugs industry currently sits down 0.3% versus the S&P 500, which is down 0.2%. On the negative front, top decliners within the industry include Shire ( SHPG), down 1.2%, Sanofi ( SNY), down 1.0% and AstraZeneca ( AZN), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Perrigo ( PRGO) is one of the companies pushing the Drugs industry higher today. As of noon trading, Perrigo is up $1.40 (0.9%) to $149.68 on average volume. Thus far, 933,294 shares of Perrigo exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $146.25-$150.31 after having opened the day at $148.25 as compared to the previous trading day's close of $148.28.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Perrigo Company plc, through its subsidiaries, develops, manufactures, and markets over-the-counter (OTC) consumer goods and pharmaceutical products worldwide. Perrigo has a market cap of $22.7 billion and is part of the health care sector. Shares are down 11.2% year-to-date as of the close of trading on Monday. Currently there are 7 analysts who rate Perrigo a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Perrigo as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full Perrigo Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Pfizer ( PFE) is up $0.29 (0.9%) to $31.62 on heavy volume. Thus far, 31.4 million shares of Pfizer exchanged hands as compared to its average daily volume of 31.3 million shares. The stock has ranged in price between $31.22-$31.62 after having opened the day at $31.38 as compared to the previous trading day's close of $31.33.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer has a market cap of $198.6 billion and is part of the health care sector. Shares are up 0.6% year-to-date as of the close of trading on Monday. Currently there are 9 analysts who rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Allergan ( AGN) is up $2.86 (0.9%) to $304.58 on heavy volume. Thus far, 4.5 million shares of Allergan exchanged hands as compared to its average daily volume of 4.5 million shares. The stock has ranged in price between $301.52-$304.75 after having opened the day at $302.25 as compared to the previous trading day's close of $301.72.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. Allergan has a market cap of $123.1 billion and is part of the health care sector. Shares are up 17.2% year-to-date as of the close of trading on Monday. Currently there are 13 analysts who rate Allergan a buy, 1 analyst rates it a sell, and none rate it a hold.

TheStreet Ratings rates Allergan as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good. Get the full Allergan Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).